Corvus Pharmaceuticals, Inc.
General ticker "CRVS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $370.3M (TTM average)
Corvus Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 52.1%.
Estimated limits based on current volatility of 3.5%: low 8.14$, high 8.74$
Factors to consider:
- Total employees count: 28 (-3.4%) as of 2023
- Top business risk factors: Lack of profitability, Fluctuating operating results, Key executive dependency, Labor/talent shortage/retention, Climate change and natural disasters
- Current price 15.9% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.14$, 7.60$]
- 2025-12-31 to 2026-12-31 estimated range: [2.27$, 5.67$]
Financial Metrics affecting the CRVS estimates:
- Positive: with PPE of -10.5 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -8.28 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Negative: Investing cash flow per share per price, % of -8.95 <= -4.48
- Negative: negative Industry operating income (median)
Short-term CRVS quotes
Long-term CRVS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $32.56MM | $23.41MM | $27.55MM |
| Operating Income | $-32.56MM | $-23.41MM | $-27.55MM |
| Non-Operating Income | $-9.92MM | $-3.78MM | $-34.74MM |
| R&D Expense | $24.47MM | $16.53MM | $19.39MM |
| Income(Loss) | $-42.48MM | $-27.18MM | $-62.29MM |
| Profit(Loss)* | $-41.31MM | $-27.03MM | $-62.29MM |
| Stockholders Equity | $56.12MM | $38.68MM | $32.57MM |
| Assets | $68.24MM | $45.55MM | $68.91MM |
| Operating Cash Flow | $-27.02MM | $-23.93MM | $-25.42MM |
| Capital expenditure | $0.27MM | $0.03MM | $0.00MM |
| Investing Cash Flow | $-23.28MM | $15.54MM | $-27.48MM |
| Financing Cash Flow | $0.00MM | $7.86MM | $49.03MM |
| Earnings Per Share** | $-0.89 | $-0.56 | $-1.02 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.